Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.
Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L, Miller CR, Perou CM, Sharpless N, Zamboni WC.
Anders CK, et al.
PLoS One. 2013 May 1;8(5):e61359. doi: 10.1371/journal.pone.0061359. Print 2013.
PLoS One. 2013.
PMID: 23650496
Free PMC article.
Median survival of PLD-treated animals was 32 days (d, [CI] 31-38), which was significantly longer than controls (26d [CI 25-28]; p = 0.0012) or NonL-doxo treatment (23.5d [CI 18-28], p = 0.0002). Combination treatment with PLD/ABT-888 yielded improved survival compared to …
Median survival of PLD-treated animals was 32 days (d, [CI] 31-38), which was significantly longer than controls (26d [CI 25-28]; p = 0.0012 …